PropertyValue
?:abstract
  • While all studies focused on the treatment efficacy of HCQ data on prevention remained blank However Boulware et2 al have published their data on the efficacy of HCQ for prevention of COVID-19 in New England Journal of Medicine It is a randomized placebo controlled double blind trial from USA and Canada Investigators enrolled 812 asymptomatic individuals with 87 6% being exposed to high risk COVID-19 contacts Individuals were assigned to receive placebo or 800 mg of HCQ as loading dose followed by 600 mg in 6-8 hours with maintenance of 600 mg daily for 4 days Primary outcome was the incidence of laboratory positive COVID-19 or symptoms compatible with COVID-19 within 14 days
is ?:annotates of
?:creator
?:journal
  • Journal_of_the_Association_of_Physicians_of_India
?:license
  • unk
?:publication_isRelatedTo_Disease
?:source
  • WHO
?:title
  • Hydroxychloroquin for COVID-19 why was so much hype?
?:type
?:who_covidence_id
  • #972926
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/fvw1ky5m>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/fvw1ky5m>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all